289 related articles for article (PubMed ID: 24420815)
21. Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer.
Hendifar A; Tan CR; Annamalai A; Tuli R
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1051-61. PubMed ID: 24898788
[TBL] [Abstract][Full Text] [Related]
22. Emerging therapies for colorectal cancer.
Hezel AF; Ryan DP
Expert Opin Investig Drugs; 2007 Jun; 16(6):867-76. PubMed ID: 17501698
[TBL] [Abstract][Full Text] [Related]
23. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
Le Tourneau C; Siu LL
Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
[TBL] [Abstract][Full Text] [Related]
24. The role of the PI3K pathway in colorectal cancer.
Papadatos-Pastos D; Rabbie R; Ross P; Sarker D
Crit Rev Oncol Hematol; 2015 Apr; 94(1):18-30. PubMed ID: 25591826
[TBL] [Abstract][Full Text] [Related]
25. EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.
Berg M; Soreide K
Discov Med; 2012 Sep; 14(76):207-14. PubMed ID: 23021375
[TBL] [Abstract][Full Text] [Related]
26. The molecular therapy of colorectal cancer.
Waldner MJ; Neurath MF
Mol Aspects Med; 2010 Apr; 31(2):171-8. PubMed ID: 20171980
[TBL] [Abstract][Full Text] [Related]
27. H-RN, a novel antiangiogenic peptide derived from hepatocyte growth factor inhibits inflammation in vitro and in vivo through PI3K/AKT/IKK/NF-κB signal pathway.
Wang L; Xu Y; Yu Q; Sun Q; Xu Y; Gu Q; Xu X
Biochem Pharmacol; 2014 May; 89(2):255-65. PubMed ID: 24630926
[TBL] [Abstract][Full Text] [Related]
28. Targeted therapeutic agents for colorectal cancer.
Chee CE; Sinicrope FA
Gastroenterol Clin North Am; 2010 Sep; 39(3):601-13. PubMed ID: 20951919
[TBL] [Abstract][Full Text] [Related]
29. Curcuma as an adjuvant in colorectal cancer treatment.
Villegas C; Perez R; Sterner O; González-Chavarría I; Paz C
Life Sci; 2021 Dec; 286():120043. PubMed ID: 34637800
[TBL] [Abstract][Full Text] [Related]
30. Cellular signaling pathways implicated in metastasis of colorectal cancer and the associated targeted agents.
Liu X; Ji Q; Fan Z; Li Q
Future Oncol; 2015; 11(21):2911-22. PubMed ID: 26414153
[TBL] [Abstract][Full Text] [Related]
31. The Treatment of Colorectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges.
Rogers JE; Dasari A; Eng C
Oncologist; 2016 May; 21(5):563-70. PubMed ID: 27000464
[TBL] [Abstract][Full Text] [Related]
32. Dietary phytochemicals in colorectal cancer prevention and treatment: A focus on the molecular mechanisms involved.
Afrin S; Giampieri F; Gasparrini M; Forbes-Hernández TY; Cianciosi D; Reboredo-Rodriguez P; Zhang J; Manna PP; Daglia M; Atanasov AG; Battino M
Biotechnol Adv; 2020; 38():107322. PubMed ID: 30476540
[TBL] [Abstract][Full Text] [Related]
33. The clinical application of fruquintinib on colorectal cancer.
Chen Z; Jiang L
Expert Rev Clin Pharmacol; 2019 Aug; 12(8):713-721. PubMed ID: 31177854
[No Abstract] [Full Text] [Related]
34. Novel and Emerging Targeted Therapies of Colorectal Cancer.
Finnberg N; Gokare P; El-Deiry WS
Curr Clin Pharmacol; 2015; 10(4):279-98. PubMed ID: 26548905
[TBL] [Abstract][Full Text] [Related]
35. From Molecular Biology to Clinical Trials: Toward Personalized Colorectal Cancer Therapy.
Palma S; Zwenger AO; Croce MV; Abba MC; Lacunza E
Clin Colorectal Cancer; 2016 Jun; 15(2):104-15. PubMed ID: 26777471
[TBL] [Abstract][Full Text] [Related]
36. Navigating Molecular Pathways: An Update on Drugs in Colorectal Cancer Treatment.
Maurya NS; Mani A
Curr Top Med Chem; 2023; 23(30):2821-2843. PubMed ID: 37317918
[TBL] [Abstract][Full Text] [Related]
37. Molecular pathways: aspirin and Wnt signaling-a molecularly targeted approach to cancer prevention and treatment.
Gala MK; Chan AT
Clin Cancer Res; 2015 Apr; 21(7):1543-8. PubMed ID: 25501125
[TBL] [Abstract][Full Text] [Related]
38. Novel antineoplastics targeting genetic changes in colorectal cancer.
Joudeh J; Allen JE; Das A; Prabhu V; Farbaniec M; Adler J; El-Deiry WS
Adv Exp Med Biol; 2013; 779():1-34. PubMed ID: 23288633
[TBL] [Abstract][Full Text] [Related]
39. Targeted nanoparticles for colorectal cancer.
Cisterna BA; Kamaly N; Choi WI; Tavakkoli A; Farokhzad OC; Vilos C
Nanomedicine (Lond); 2016 Sep; 11(18):2443-56. PubMed ID: 27529192
[TBL] [Abstract][Full Text] [Related]
40. Signaling pathways involved in colorectal cancer progression.
Koveitypour Z; Panahi F; Vakilian M; Peymani M; Seyed Forootan F; Nasr Esfahani MH; Ghaedi K
Cell Biosci; 2019; 9():97. PubMed ID: 31827763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
